Rocket Pharmaceuticals (RCKT) Insider Trading & Ownership $14.11 +0.01 (+0.07%) (As of 11/26/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage28.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$12.03 M Get RCKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Rocket Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address RCKT Insider Buying and Selling by Quarter Ad Behind the Markets📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Rocket Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/21/2024Gaurav ShahCEOSell11,091$13.05$144,737.55 11/21/2024John MilitelloInsiderSell1,224$13.05$15,973.20 11/21/2024Martin WilsonGeneral CounselSell1,175$13.05$15,333.75 7/22/2024John MilitelloInsiderSell812$23.02$18,692.24 7/8/2024Mark Andrew WhiteInsiderSell3,026$20.39$61,700.14 5/16/2024Gaurav ShahCEOSell9,790$23.35$228,596.50 Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide5/16/2024John MilitelloInsiderSell1,079$23.35$25,194.65 5/16/2024Martin WilsonGeneral CounselSell1,048$23.35$24,470.80 4/22/2024John MilitelloInsiderSell833$22.87$19,050.71 4/15/2024David P SouthwellDirectorSell10,000$24.05$240,500.00 4/12/2024David P SouthwellDirectorSell70,000$24.36$1,705,200.00 4/8/2024Mark Andrew WhiteInsiderSell12,532$24.64$308,788.48 3/21/2024Gotham MakkerDirectorSell274,000$28.43$7,789,820.00 3/21/2024John MilitelloInsiderSell2,490$28.10$69,969.00 2/29/2024John MilitelloInsiderSell10,000$29.84$298,400.00 2/29/2024Martin WilsonGeneral CounselSell4,100$29.33$120,253.00 2/16/2024Gaurav ShahCEOSell20,272$29.84$604,916.48 2/16/2024Kinnari PatelInsiderSell7,132$29.84$212,818.88 2/16/2024Martin WilsonGeneral CounselSell3,576$29.84$106,707.84 1/22/2024John MilitelloInsiderSell638$27.20$17,353.60 (Data available from 1/1/2013 forward) RCKT Insider Trading Activity - Frequently Asked Questions Who is on Rocket Pharmaceuticals's Insider Roster? The list of insiders at Rocket Pharmaceuticals includes David P Southwell, Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel, Mark Andrew White, Martin Wilson, and Rtw Investments, Lp. Learn more on insiders at RCKT. What percentage of Rocket Pharmaceuticals stock is owned by insiders? 28.50% of Rocket Pharmaceuticals stock is owned by insiders. Learn more on RCKT's insider holdings. Which Rocket Pharmaceuticals insiders have been selling company stock? The following insiders have sold RCKT shares in the last 24 months: David P Southwell ($1,945,700.00), Gaurav Shah ($1,284,413.66), Gotham Makker ($8,457,281.36), John Militello ($528,837.73), Jonathan David Schwartz ($67,796.42), Kinnari Patel ($236,549.86), Mark Andrew White ($370,488.62), and Martin Wilson ($266,765.39). How much insider selling is happening at Rocket Pharmaceuticals? Insiders have sold a total of 500,661 Rocket Pharmaceuticals shares in the last 24 months for a total of $13,157,833.04 sold. Rocket Pharmaceuticals Key ExecutivesMs. Kinnari Patel M.B.A. (Age 44)Pharm.D., Head of R&D, President & COO Compensation: $849.93kMr. Mayo Pujols (Age 54)Chief Technical Officer Compensation: $649.71kMr. Raj Prabhakar M.B.A. (Age 49)Chief Business Officer Compensation: $619.13kMr. Aaron Ondrey (Age 47)Chief Financial Officer Mr. Martin Louis Wilson J.D. (Age 48)General Counsel, Chief Compliance Officer & Chief Corporate Officer Compensation: $149.95kKevin GiordanoDirector of Corporate CommunicationsMs. Isabel Carmona J.D.Chief People OfficerMr. Jonathan Schwartz M.D. (Age 59)Chief Medical & Gene Therapy Officer Compensation: $557.79kDr. Gayatri R. Rao J.D.M.D., Senior VP of Clinical Safety & Chief Regulatory OfficerMr. Carlos MartinChief Commercial Operations & Revenue Officer More Insider Trading Tools from MarketBeat Related Companies BridgeBio Pharma Insider Ownership ADMA Biologics Insider Ownership Arcellx Insider Ownership Biohaven Insider Ownership Ultragenyx Pharmaceutical Insider Ownership Organon & Co. Insider Ownership Apellis Pharmaceuticals Insider Ownership Immunovant Insider Ownership Rhythm Pharmaceuticals Insider Ownership Scholar Rock Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:RCKT) was last updated on 11/27/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
